HEAD AND NECK SQUAMOUS CELL CANCER
Clinical trials for HEAD AND NECK SQUAMOUS CELL CANCER explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CANCER trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New injection fights head and neck cancer from the inside
Disease control Recruiting nowThis early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The ma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: VLP Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:35 UTC